Untreated patients with Hodgkin's disease (HD) have a blood T-lymphocytopenia mainly caused by a reduction of the CD4+ subset. Indirect support for a sequestration of T cells in the spleen and tumor-involved lymphoid tissue has accumulated. To test the hypothesis that the blood CD4 T-lymphocytopenia in patients with HD is caused by an altered lymphocyte traffic, 12 untreated HD patients and five in complete clinical remission (CCR) were studied. Blood lymphocytes were collected by leukapheresis and gradient centrifugation, and were further purified by an adherence step. The cells were labeled with indium-111 oxine and reinfused intravenously into the patient. The
T disease (HD), including those with limited disease, exhibit impaired cell-mediated immunity and a reduced number of circulating T cells as well as alterations in the relative proportion of phenotypically and functionally distinct T-cell subsets.'-4 The T-lymphocytopenia is mainly attributed to a lack of CD4+
Decreased in vitro synthesis of interleukin-2 (IL-2) and interferon-y has also been reported in both untreated and treated patients with HD.6*7 A persisting functional immune defect has been documented in long-term survivors after successful therapy. T-lymphocytopenia is also a characteristic of patients in continuous unmaintained complete remission, in particular after radiotherapy, although the lymphocyte count seems to recover a t a slow rate. ' Although T-lymphocytopenia is present in all clinical stages, it tends to be more pronounced in patients with advanced disease. Moreover, patients with B symptoms usually have lower lymphocyte counts than asymptomatic cases, possibly reflecting the lower proportion of stage III/IV disease among the Most studies have not demonstrated any association between blood lymphocyte counts and histopathology, age, or sex. It may be concluded that H D patients not exposed to cytoreductive treatment display a decrease in total and relative CD4+ cell counts that is associated with the extent of disease."
The mechanisms of the T-lymphocytopenia and of the T-cell deficiency in H D are unknown, but may be due to decreased production, increased destruction, or maldistribution of lymphocytes among lymphoid compartments. Consequently, an altered lymphocyte traffic may contribute to the T-lymphocytopenia and to a relative change in blood T-cell subsets. Indirect support for the sequestration of T cells in the spleen and tumor-involved lymphoid tissues has accumulated.">l2 Thus far, the information from previous studies of lymphocyte traffic in H D has been limited by either the use of indirect m e t h o d~'~ or has not been given consideration to the T-cell subpopulations i n v~l v e d . l~-'~ In this report we have used indium-1 11 labeled autologous blood lymphocytes to study the elimination of CD4+ and CD8+ cells from the blood in patients with HD. The results unequivocally show selective increase in the elimination rate of the CD4+ cells in patients with active HD. 
PATIENTS AND METHODS

Patients
The patient series include 7 women and 9 men with a median age of 36 years (range 16 to 65 years). Patient characteristics and clinical data are presented in Table 1 . One patient (no. 9) was studied before and after successful chemotherapy. There were 12 previously untreated patients and five patients in complete clinical remission (CCR). Patients who had undergone splenectomy or who received radiotherapy to the spleen were excluded from the study, as were severely ill patients requiring prompt institution of therapy. Clinical staging followed the Ann Arbor recommendations,I6 and histopathology was subclassified according to the Rye nomenclature." In one patient (no. 2), the diagnosis of HD was established after cytologic examination of tumor tissue (for further details on clinical procedures see references 18 and 19). The control series of blood lymphocyte subset studies consisted of 108 healthy hospital staff members with a median age of 32 years (range 18 to 74 years). The study was approved by the Ethics Committee at Karolinska Institute and the Isotope Committee at Karolinska Hospital, Stockholm, Sweden. All patients gave informed consent.
Methods
The various methodologic steps are summarized in Fig 1. centrifugation for 25 minutes the cells in the lymphocyte-rich interphase layer were harvested and washed three times with HSS containing 5% human albumin; the first wash at 600g for 75 seconds, the second at 400g for 60 seconds, and the third at 340g for 60 seconds. The lymphocyte-rich pellet was resuspended in HSS with albumin and the cells were counted. To purge the suspension from monocytes and granulocytes, 10' cells in 30 mL balanced salt solution (BSS) with 10% autologous fresh plasma were added to plastic bottles (600 mL/ 175 cm2; Nunc Intermed, Roskilde, Denmark). The cells were incubated at 37OC for 1 hour. After gentle shaking the nonadherent cells were removed. The bottles were rinsed once with BSS and nonadherent cells were pooled. Cell aggregates were removed by sedimentation for 2 minutes and the nonaggregated cells in the supernatant were counted. After centrifugation of the supernatant at 400g for 10 minutes, the cells were resuspended in 5 mL BSS with 5 MBq indium-111 oxine per lo9 cells. After incubation for 15 minutes, 15 mL BSS and 5 mL autologous plasma were added. After centrifugation at 400g for 10 minutes, the supernatant was removed and the cells were resuspended in 10 mL saline and counted. The radioactivity was measured and a sample was collected for T-cell subset separation (see below). The procedure was performed under strict sterile conditions. The labeled cell suspension was infused intravenously over 1 to 2 minutes.
GRIMFORS ET AL
Two to four blood samples were drawn from each patient at different intervals.
Lymphocytes were enriched by Ficoll-Isopaque (Pharmacia, Uppsala, Sweden) gradient centrifugation of heparinized venous blood. After incubation with iron powder, phagocytic cells were removed by a magnet. 20 The lymphocyte suspensions contained more than 98% viable lymphocytes as assessed by trypan blue exclusion test.
T cells and subsets were identified using monoclonal antibodies (MoAbs) OKT3 (CD3), OKT4 (CD4), and OKT8 (CD8) (Ortho Pharmaceutical Corp, Raritan, NJ) in indirect immunofluorescence using a fluorescein-conjugated absorbed goat anti-mouse IgG (Meloy Lab, Springfield, VA) in the second step as described previously." Two hundred to 400 cells were counted using a Leitz Dialux 20 B fluorescence microscope (Ernst
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Leitz, GMBH, Wetzlar, West Germany) with epi-illumination in ordinary light and UV light at 1,000 magnification.
For determination of radioactivity in the CD4' and CD8+ cell subsets, respectively, the following technique was used in the first seven experiments. Lymphocytes were separated into T and non-T cells by a rosetting technique. Sixty to 80 x lo6 lymphocytes were suspended in 5 mL of RPMI 1640 (Flow Laboratories, Irvine, Ayrshire, Scotland) with 10 mmol/L HEPES buffer and 20% fetal calf serum (FCS; Flow Laboratories) and mixed with 1 mL of 10% neuraminidase (Sigma Chemical Co, St Louis, MO) treated sheep red blood cells (SRBC) in 100% FCS. The cells were incubated at 37OC for 15 minutes, centrifuged for 5 minutes at 15Og. and then incubated for 2 hours on ice. The pellet was then gently resuspended and layered onto a Ficoll-Isopaque gradient. After centrifugation for 20 minutes at 600g. unrosetted cells (nowT-cell fraction) were removed from the interphase layer and washed twice in 0.15 mol/L Hanks Tris (HT) buffer. The pellet (T-cell fraction) was resuspended in 5 mL of RPMI with 10% FCS and incubated at 37OC for 15 minutes and agitated on a Vortex. After centrifugation for 6 minutes at 600g. SRBCs were lysed after the addition of 1 mL of distilled water and 0.5 mL of HT containing 10% FCS. The cell suspension was agitated on a Vortex (Scientific Industries, Bohemia, NY) for 20 to 30 seconds and 8 mL of HT was added. The cells were washed twice in HT.
Polyvalent rabbit anti-mouse immunoglobulin G (IgG; Dako/AS, Copenhagen, Denmark) was purified on cyanogen bromideactivated Sepharose (Pharmacia) coated with normal mouse IgG diluted in trypsin buffer without Ca2+ and Mg*+. Two milliliters of the anti-mouse IgG (12.25 g of protein/mL) was added to plastic Petri dishes (Falcon 3002; Becton Dickinson, Oxnard, CA). After gentle agitation for 1 hour at room temperature, the dish was rinsed twice with trypsin buffer. Two milliliters of Protein A (50 pg/mL) (Pharmacia), diluted in trypsin buffer, was then added to each dish followed by gentle agitation for 1 hour at room temperature. The dish was rinsed twice with trypsin buffer, and 2 mL of trypsin buffer with 20% FCS were added to each dish. Lymphocytes, 15 x106, (T-cell fraction) in 0.1 mL of RPMI 1640 with 5% FCS and 0.1 mL of OKT4 or OKT8 MoAbs, respectively (diluted ]:loo), were incubated on ice for 1 hour and washed three times with trypsin buffer containing 5% FCS. The cells were suspended in 2 mL of typsin buffer with 20% FCS and poured onto the coated dishes. The cells were allowed to settle during one centrifugation (5 minutes at 15Og). The nonbound cells were collected after gentle tilting of the dish. The dishes were washed twice with RPMI 1640 containing 5% FCS. The nonbound cells were washed three times in HSS. Lymphocyte subpopulations were characterized and enumerated by indirect IFL using MoAbs (see above). The radioactivity of all samples from each patient was measured in a y counter (Wallac, Turku, Finland) on the same occasion.
In the last 10 experiments the following technique was used for cell separation and radioactivity measurement of indium-1 11 oxinelabeled T-cell subsets.
Lymphocytes were isolated as described above. MoAbs OKT4 or OKT8 were mixed with the cells, respectively (50 pg/106 cells). The T-cell subset separation. cells were incubated for 30 minutes on ice and washed twice. Dynabeads M450 sheep anti-mouse IgG (Dynal AS, Oslo, Norway), 7.5 pL, were added to lo6 cells and incubated for 30 minutes on ice. Cells bound to the beads were removed by a magnet and resuspended in 2 mL of phosphate-buffered saline. The relative proportion of CD4+ and CD8+ cells was analyzed using Simultest (Becton Dickinson) and flow-cytometry (FACScan; Becton Dickinson). The radioactivity was determined as described above.
The following formula was used to define the proportion of remaining blood lymphocyte radioactivity: (A x B x C)/(D x E x F), where A = radioactivity (mean cpm/106 CD4+ or CD8+ cells); B = estimated number of circulating lymphocytes in the blood (calculated using an Calculation of blood lymphocyte radioactivity.
RESULTS
The median number of autotransfused labeled cells was 1.0 x109 (range 0.2 to 2.6 x lo9). The cell suspensions contained 90% lymphocytes (median; range 83% to 95%) and the viability (trypan blue exclusion test) was greater than 95% in all tested samples. The labeling efficiency of the radionuclide was 83% (median; range 79% to 90%) and total radioactivity infused was 6.3 MBq (median; range 1.9 to 12.3 MBq). Radioactivity per 10' cells varied between 0.3 MBq (7.1 pCi) and 1.1 MBq (29.1 pCi; median 0.7 MBq, 18.6 pCi) .
The total blood lymphocyte count as well as total CD4+ and CD8+ cell counts were significantly lower in the patient group as compared with controls (P < .01; Student's unpaired t-test; Table 2 ). There was no statistical difference in total lymphocyte counts or subsets between untreated patients and patients in complete remission (P > .05; MannWhitney, nonparametric test). However, the proportion of CD4+ cells was lower in patients in clinical remission (P < .05, Mann-Whitney, nonparametric test). The proportion of the CD8+ cells did not differ between the two patient groups (Tables 2 and 3) .
Between the first and last test after infusion of the autologous lymphocyte suspension, a decrease of the radiolabeled CD4+ cell fraction was recorded. This decrease was 54% (median) in untreated patients, but only 8% in CCR patients (P < .01; Wilcoxon-Mann-Whitney test; Fig 2, Table 3 ). The corresponding values for the radio-labeled CD8+ cells were 23% and 28%, respectively (P > .05; Fig 3, Table 3 ). As a consequence, the ratio between the residual radio-labeled CD4+ and CD8+ cell fractions in peripheral blood decreased in all previously untreated patients, while increased ratios were observed in the five patients in CCR (P < .001, Wilcoxon-Mann-Whitney test ; Fig 4) . No association between the elimination rate of either T-cell subset and clinical variables such as stage, age, histopathology, or sex was observed (Tables 1 and 3) . The elimination rate of CD4+ cells was positively correlated with both relative and total number of blood CD4+ cells (P < .001 and P < .01, respectively; simple regression analysis), but not to total lymphocyte or total or relative CD8+ cell count (Tables 1 and 3) . A similar relationship between the elimination rate of CD8+ and the relative or total numbers of the same T-cell subset was not found. In support of the hypothesis of an altered distribution of T cells are studies showing increased proportions of T lymphocytes, and especially CD4+ cells, in tumor-involved tissue and spleens." The increased mitogenic responsiveness of splenic lymphocytes, which has been o b s e r~e d ,~~-*~ and the strong inverse correlation between spleen weight and blood lymphocyte DNA synthesis induced by mitogens in HD patients with splenic involvement indirectly suggests a sequestration of T cells in the spleen.26s27
Recirculating lymphocytes traffic continuously between the blood and the lymph. Although the cells circulate freely in the blood stream, they seem to seek out those blood vessels that provide entry into specific lymphoid tissues." The high endothelial cell venules (HEV) is the first barrier for the lymphocytes on their way from the blood into the tissue.
Lymphocytes bind through the receptor to specific HEV structures, and that is the first step in the movement across the capillary wall.29 Only recently Freedman et aI3' demonstrated that activated T cells and B lymphocytes in particular exhibit preferential adherence to the germinal center of the lymphoid follicle.
To explain the altered distribution of T-cell subsets in HD, a failure of T-cell migration and recirculation with a preferential accumulation of T cells within the spleen and tumorinvolved lymph nodes (ecotaxopathy) has been suggested.'* A lectin-binding galactose structure (HD lectin) on the surface of cultured HD cells as well as in HD involved tissue has been ~haracterized.~' This HD lectin binding structure functions as a receptor for T lymphocytes and is capable of mediating stimulation of the agglutinated lymphocytes. It was postulated that the interaction between these two cell types results in mutual activation and stimulation of H D cell growth and rosette formation between Reed-Sternberg cells and, mainly, CD4+ lymphocytes. Such a mechanism is compatible with an increased depletion of CD4+ cells from the blood and the suggested sequestration of CD4+ cells in HI) tumor-involved tissue. Moreover, IL-2 production has been reported to be impaired in H D patients and might be a consequence of a diminished CD4 cell pool, which is the main producer of IL-2. The understanding of lymphocyte migration has, to a great extent, been derived from studies using indium-1 1 1 oxinelabeled cell^.^^*'^ Alternative radionuclides such as "Cr have definite shortcomings with respect to labeling efficiency, poor y camera imaging characteristics, long half-life (28 days), and dissociation of the radionuclide from lymphocytes. However, with the introduction of indium-1 11 oxine as an alternative labeling procedure, progress within this field has been made in humans.32 Using this technique, further evidence for lymphocyte trapping has been demonstrated in HD. An increased accumulation of labeled blood lymphocytes was seen in tumor-involved lymph node^.'^*^^
The functional integrity of indium-1 11 oxine-labeled lymphocytes has been q~estioned,'~ but the consensus is that a labeling dose of 3.7 MBq (100 pCi)/108 cells or less does not seem to influence lymphocyte kinetics and has been proposed for short-term lymphocyte migration studies. 35 However, even at this dose there appears to be an increased frequency of chromosomal aberrations in indium-1 1 1 oxine-labeled lymphocytes, and the risk for secondary lymphoid malignancies must be c o n~i d e r e d .~~ Nevertheless it should be stressed that the significance of chromosomal aberrations is largely unknown and the risk for tumor induction appears to be extremely
In the present study the median radioactivity per lo8 cells did not exceed 1.1 MBq (29.1 pCi) in any patient.
The hypothesis of this study was that CD4+ cells would be eliminated faster from the blood stream in patients with untreated H D as compared with cured patients. This would support the notion of a sequestration of CD4+ blood cells into tumor-involved nodes. The results of the study unequivocally confirm a faster elimination of CD4+ cells from the blood in patients with active disease compared with patients in CCR. Furthermore, the labeled CD4+ cells decreased more rapidly than the CD8+ cells in the untreated patients. There were no differences in clinical stage, histopathology, sex, age, number of autotransfused labeled cells, or radioactivity bound to infused cells between the two patient groups. No difference was seen in total lymphocytes or subset cell numbers between untreated patients and patients in CCR, but the proportion of CD4+ cells was lower in CCR patients. The low lymphocyte and subset counts in CCR patients is explained by the effect of combination chemotherapy and/or radiotherapy also seen in patients with diseases other than HD.73'0 Ideally, comparisons should be made using healthy volunteers, but such an approach has not been accepted from an ethical standpoint a t our institution. In untreated patients of this study with a faster elimination of CD4+ cells from the blood we have also observed, by y camera imaging, an accumulation of radionuclide in enlarged lymph nodes." However, such a pattern was not seen in CCR patients. The fast elimination of CD4+ cells from blood of patients with active H D compared with patients in CCR, and an accumulation of radioactivity in tumor-involved lymph nodes strongly support the hypothesis of a sequestration of CD4+ lymphocytes in tumor-involved tissues. The existence of tumor-specific cytotoxic T lymphocytes in human tumors36 are most interesting for future cancer therapy. Such tumor-specific T lymphocytes might reside within the CD4+ cell population. Another potential effective treatment of H D might be the use of indium-1 14m, a long half-life P-emitting radionuclide that can be chelated with oxine in the same way as indium-1 11 and labeled to autologous lymphocyte^.^^ The cells migrate normally and a selective internal irradiation of lymphoid tissue might be ~btained.'~ Treatment of H D with indium-1 14m-labeled autologous cells could possibly be more sensitive and effective if purified CD4+ cells were used. This is the first demonstration of in vivo lymphocyte maldistribution and homing to tumor-involved sites as a cause of immunodeficiency. The importance of these results lies not only in the demonstration of lymphocyte kinetics as a tool in clinical immunologic studies, but also in the potential use of such a technique in diagnosis and further treatment. 
